The market is mainly driven by increasing prevalence of valvular
diseases, increasing demand for minimally invasive surgeries (MISs), rise in
number of clinical trials for heart valves, and introduction of advanced
The different types of valves available in the aortic valve market are
transcatheter valves, sutureless valves and others. Among these, transcatheter
valves attained the largest share of 58.8% in the market, in 2017. This leading
position of the category is attributed to increasing initiatives for research
activities for developing transcatheter valves and increasing number of
clinical trials to study transcatheter valves. For instance, In December 2017,
Edwards Lifesciences Corporation announced new data demonstrating the economic
advantages of the company's SAPIEN 3 transcatheter aortic valve.
Report Summary: https://www.psmarketresearch.com/market-analysis/aortic-valve-market
On the basis of type of surgery, aortic valve market is segmented into
MIS and open surgery. The adoption of these valves for MISs is expected to grow
at a faster CAGR of 13.7% during the forecast period. MISs causes lesser trauma
to the patient and facilitate quicker recovery than invasive procedures such as
open-heart surgeries. Due to reduced prices and advantages, there is an
increase in the adoption of minimally invasive procedures, which contribute in
the growth of the market.
Request to Get the
Sample Pages at: https://www.psmarketresearch.com/market-analysis/aortic-valve-market/report-sample
During the forecast period, the aortic valve industry is expected to
witness the fastest growth in demand in Asia-Pacific (APAC), at a CAGR of
13.0%, owing to the presence of large number of patient population with
cardiovascular diseases, rising number of aortic valve replacement surgeries,
growing medical tourism, and continuously improving healthcare infrastructure.
Make Enquiry Before
Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=aortic-valve-market
In December 2017, CryoLife Inc., announced the enrolment of patients
for the company's BioGlue clinical trial in China. The result from the trial
will serve as the company's regulatory submission to the Chinese Food and Drug
Administration (CFDA) to gain approval to commercialize BioGlue in the country.
Globally, key players in the aortic valve industry are seeking for
approvals to launch new products in the market. For instance, in February 2018,
Edwards Lifesciences Corporation received CE Mark for its self-expanding
CENTERA valve for severe, symptomatic aortic stenosis patients at high risk of
open surgery. In March 2018, LivaNova Plc received CE Mark approval for its
Bicarbon aortic valves for use with low-dose anticoagulant therapy. This
expanded indication of the company's Bicarbon family of mechanical valves is
based on evidence and results from the LOWERING-IT trial.
Some of the other key players operating in the aortic valve market are
Medtronic plc and Boston Scientific Corporation.